Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Feb. 28, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Trading Symbol	RKDA
Entity Registrant Name	ARCADIA BIOSCIENCES, INC.
Entity Central Index Key	0001469443
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		44,508,709
Entity Public Float			$ 18,700,000

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 2,013	$ 23,973
Short-term investments	48,547	26,270
Accounts receivable	349	706
Unbilled revenue	184	82
Inventories — current	252	294
Prepaid expenses and other current assets	877	692
Total current assets	52,222	52,017
Property and equipment, net	508	585
Inventories — noncurrent	1,327	1,867
Long-term investments	2,498	19,748
Other noncurrent assets	19	25
Total assets	56,574	74,242
Current liabilities:
Accounts payable and accrued expenses	2,359	2,423
Amounts due to related parties	30	19
Unearned revenue — current	740	1,008
Total current liabilities	3,129	3,450
Notes payable	25,127	24,930
Unearned revenue — noncurrent	3,120	2,637
Other noncurrent liabilities	3,000	3,000
Total liabilities	34,376	34,017
Stockholders’ equity:
Common stock, $0.001 par value—400,000,000 shares authorized as of December 31, 2016 and December 31, 2015; 44,487,678 and 44,184,195 shares issued and outstanding as of December 31, 2016 and December 31, 2015, respectively	44	44
Additional paid-in capital	173,723	172,222
Accumulated deficit	(151,550)	(131,926)
Accumulated other comprehensive loss	(19)	(115)
Total stockholders’ equity	22,198	40,225
Total liabilities and stockholders’ equity	$ 56,574	$ 74,242

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	400,000,000	400,000,000
Common stock, issued	44,487,678	44,184,195
Common stock, outstanding	44,487,678	44,184,195

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product	$ 669,000	$ 466,000
License	144,000	1,216,000
Contract research and government grants	2,375,000	3,732,000
Total revenues (which includes $0 and $91 from related parties — Note 16)	3,188,000	5,414,000
Operating expenses:
Cost of product revenues	895,000	892,000
Research and development	8,663,000	8,966,000
Selling, general and administrative	12,250,000	11,119,000
Total operating expenses	21,808,000	20,977,000
Loss from operations	(18,620,000)	(15,563,000)
Interest expense	(1,319,000)	(2,658,000)
Other income, net	340,000	521,000
Loss on extinguishment of debt	0	(230,000)
Net loss before income taxes	(19,599,000)	(17,930,000)
Income tax provision	(25,000)	(26,000)
Net loss	(19,624,000)	(17,956,000)
Accretion of redeemable convertible preferred stock to redemption value		(2,574,000)
Deemed dividends to warrant holder		(197,000)
Net loss attributable to common stockholders	$ (19,624,000)	$ (20,727,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.44)	$ (0.73)
Weighted-average number of shares used in per share calculations:
Basic and diluted	44,366,816	28,559,119
Other comprehensive income (loss), net of tax
Unrealized gains (losses) on available-for-sale securities	$ 96,000	$ (115,000)
Other comprehensive income (loss)	96,000	(115,000)
Comprehensive loss attributable to common stockholders	$ (19,528,000)	$ (20,842,000)

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenues from related parties	$ 0	$ 91

Consolidated Statements of Redeemable and Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2014	$ (84,766)				$ 29,204	$ (113,970)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2014				2,074,030
Temporary Equity, Beginning Balance at Dec. 31, 2014		$ 34,098	$ 48,783
Temporary Equity, Beginning Balance, Shares at Dec. 31, 2014		9,587,764	23,385,029
Exercise of stock options	$ 361			$ 1	360
Exercise of stock options, Shares	609,066			609,066
Stock-based compensation	$ 1,392				1,392
Accretion of redeemable convertible preferred stock to redemption value	(2,574)	$ 2,574			(2,574)
Preferred stock conversion to common stock upon the IPO	85,455	$ (36,672)	$ (48,783)	$ 33	85,422
Preferred stock conversion to common stock upon the IPO, Shares		(9,587,764)	(23,385,029)	32,972,793
Issuance of common stock upon the IPO, net of issuance costs of $9,799	58,428			$ 8	58,420
Issuance of common stock upon the IPO, net of issuance costs of $9,799, Shares				8,528,306
Reclassification due to re- incorporation upon the IPO				$ 2	(2)
Deemed dividends to common stock warrant holder	(197)				(197)
Increase in value of common stock warrant due to modification	197				197
Other comprehensive income loss	(115)						$ (115)
Net loss	(17,956)					(17,956)
Stockholders Equity, Ending Balance at Dec. 31, 2015	40,225			$ 44	172,222	(131,926)	(115)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2015				44,184,195
Temporary Equity, Ending Balance at Dec. 31, 2015		$ 0	$ 0
Temporary Equity, Ending Balance, Shares at Dec. 31, 2015		0	0
Exercise of stock options	$ 270				270
Exercise of stock options, Shares	228,141			228,141
Issuance of shares related to employee stock purchase plan	$ 172				172
Issuance of shares related to employee stock purchase plan, Shares				75,342
Stock-based compensation	1,059				1,059
Other comprehensive income loss	96						96
Net loss	(19,624)					(19,624)
Stockholders Equity, Ending Balance at Dec. 31, 2016	$ 22,198			$ 44	$ 173,723	$ (151,550)	$ (19)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2016				44,487,678

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (19,624,000)	$ (17,956,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	304,000	294,000
Loss (gain) on disposal of equipment	4,000	(10,000)
Net amortization of investment premium	140,000	85,000
Payment of research and develop fees with cost investment		500,000
Stock-based compensation	1,059,000	1,392,000
Change in fair value of derivative liabilities related to convertible promissory notes		9,000
Gain on expiration of warrant and derivative liability related to notes payable upon IPO		(437,000)
Accretion of debt discount	198,000	837,000
Loss on extinguishment of debt	0	230,000
Changes in operating assets and liabilities:
Accounts receivable	357,000	336,000
Unbilled revenue	(102,000)	298,000
Inventories	582,000	412,000
Prepaid expenses and other current assets	(185,000)	(415,000)
Other noncurrent assets	5,000	49,000
Accounts payable and accrued expenses	(19,000)	125,000
Amounts due to related parties	11,000	(37,000)
Unearned revenue	215,000	(821,000)
Net cash used in operating activities	(17,055,000)	(15,109,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment		10,000
Purchases of property and equipment	(231,000)	(151,000)
Purchases of investments	(41,385,000)	(48,719,000)
Proceeds from sales and maturities of investments	36,315,000	2,500,000
Net cash used in investing activities	(5,301,000)	(46,360,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock upon IPO		68,227,000
Payments of IPO issuance costs		(8,205,000)
Proceeds from issuance of notes payable		45,000,000
Payments of debt issuance costs	(46,000)	(396,000)
Payments of debt extinguishment costs		(1,319,000)
Proceeds from exercise of stock options and purchases through ESPP	442,000	360,000
Payments on notes payable to related party		(8,000,000)
Payments on notes payable and convertible promissory notes		(26,796,000)
Net cash provided by financing activities	396,000	68,871,000
Net (decrease) increase in cash and cash equivalents	(21,960,000)	7,402,000
Cash and cash equivalents — beginning of period	23,973,000	16,571,000
Cash and cash equivalents — end of period	2,013,000	23,973,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	1,033,000	2,050,000
Cash paid for income taxes	$ 29,000	149,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Accretion of redeemable convertible preferred stock		2,574,000
Debt issuance costs included in accounts payable and accrued expenses		46,000
Reclassification of deferred IPO costs to equity		5,022,000
Deemed dividends to common stock warrant holder		197,000
Issuance of warrants and derivatives in connection with notes payable issuance		437,000
Stock option exercise cost included in accounts receivable		1,000
Conversion of preferred stock to common stock upon IPO		$ 85,455,000

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2016
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Organization Arcadia Biosciences, Inc. (the "Company"), was incorporated in the state of Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Seattle, Washington; Phoenix, Arizona; and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015. The Company is an agricultural biotechnology trait company engaged in the development of traits that improve food, feed and fiber crops, and enhance the value of the resulting agricultural products. Its traits are focused on high-value enhancements that increase crop yields by enabling plants to more efficiently manage environmental and nutrient stresses, and that enhance the quality and value of agricultural products. In February 2012, the Company formed Verdeca LLC ("Verdeca", see Note 7), which is jointly owned with Bioceres, Inc. ("Bioceres"), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres S.A. is an agricultural investment and development cooperative. Verdeca, which is consolidated by the Company, was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. Reverse Stock Split In April 2015, the Company’s board of directors approved an amended and restated certificate of incorporation to effect a reverse split on the Company’s issued and outstanding common stock at a one-for-four ratio. In May 2015, the Company’s stockholders approved the certificate of amendment, which the Company filed on May 8, 2015 with the Secretary of State of Delaware to effect the reverse split. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented. The consolidated financial statements have also been retroactively adjusted to reflect a proportional adjustment for the conversion ratio for each series of redeemable convertible preferred stock and convertible preferred stock. Initial Public Offering In May 2015, the Company completed an initial public offering (“IPO”) and subsequently in June 2015, the Company completed the sale of additional shares upon exercise of the underwriters’ over-allotment option. In connection with the IPO, the Company issued 8,528,306 shares of common stock at $8.00 per share, which raised $58.4 million in proceeds, net of underwriting discounts and commissions of $4.8 million and offering expenses of $5.0 million. At the closing of the IPO, all of the outstanding shares of convertible preferred stock and redeemable convertible preferred stock were automatically converted into 32,972,793 shares of common stock. Following the IPO, there were no shares of preferred stock outstanding. In connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation to change the authorized capital stock to 400,000,000 shares designated as common stock and 20,000,000 shares designated as preferred stock, all with a par value of $0.001 per share.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The consolidated financial statements include the accounts of the Company and Verdeca LLC. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. The Company evaluates its relationships with the VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, costs to complete government grants and research contracts, reserves for inventory, and the development period of revenue-generating technologies. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers any liquid investments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2016 and 2015, a substantial portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits.

Investments in Equity and Debt Securities

The Company uses the equity method to account for investments in equity securities if the investment provides the Company the ability to exercise significant influence over operating and financial policies of the investee. The Company includes its proportionate share of earnings and/or losses of the equity method investee in its Consolidated Statements of Operations and Comprehensive Loss. The carrying value of the equity investments is reported using the equity method in the Consolidated Balance Sheets. As of December 31, 2016 and 2015, the Company’s investment in Limagrain Cereal Seeds LLC (“LCS”) is $0. See Note 6 – Investments in Unconsolidated Entity for additional information.

Investments in equity securities in which the Company holds less than 20% voting interest and on which the Company does not have the ability to exercise significant influence or account for under the equity method and do not have readily determinable fair values for are accounted for under the cost method. Cost method investments are originally recorded at cost and are reported on the Consolidated Balance Sheets.

Investments in debt securities are carried at fair value and classified as available-for-sale. Realized gains and losses on available-for-sale securities are included in other income (loss) — net in our Consolidated Statements of Operations and Comprehensive Loss. Unrealized gains and losses, net of deferred taxes, on available-for-sale securities are included in our Consolidated Balance Sheets as a component of accumulated other comprehensive income (loss) ("AOCI”). Securities classified as available-for-sale are reported as cash and cash equivalent, short-term investments or long-term investments in the Consolidated Balance Sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date. The Company’s debt securities are primarily comprised of U.S. government securities, U.S. government agency securities, commercial paper, certificates of deposit, and money markets. These available-for-sale investments are held in the custody of a major financial institution.

Other-than-Temporary Impairments on Investment

The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2016 and 2015, there was no impairment of the Company’s investments.

Accounts Receivable

Accounts receivable represents amounts owed to the Company from product sales, licenses and contract research and government grants. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had no amounts reserved for doubtful accounts at December 31, 2016 and 2015 as the Company expected full collection of the accounts receivable balances as of each of these dates.

SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil Inventory

Proprietary safflower plants are grown, producing seed with a high-GLA content. This seed is used for subsequent plantings or processed, and sold as GLA oil, including SONOVA 400 GLA safflower oils and SONOVA Ultra GLA safflower oil, which we refer to as our SONOVA products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops and costs to process and store harvested seed. Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or market or net realizable value. The Company makes adjustment to inventory when conditions indicate that the selling price may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The reserves are based upon estimates about future demand from the Company’s customers and distributors and market conditions.

The inventories—current line item in the balance sheet consists of the cost of oil inventory forecasted to be sold in the next 12 months, as of the balance sheet date. The inventories—noncurrent line item consists of oil and seed inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date.

Raw materials inventories consist primarily of seed production costs incurred by our contracted cooperators. Finished goods inventories consist of GLA oil that is available for sale. The Company recorded a $0.5 million and $0.6 million write-down of inventory for the years ended December 31, 2016 and 2015, respectively. Inventories consist of the following (in thousands):

	As of December 31,
	2016		2015
Raw Materials	$	44	$	665
Finished Goods		1,535		1,496
Inventories	$	1,579	$	2,161

Property and Equipment

Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:

	Years
Laboratory equipment	5
Software and computer equipment	3
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

*	Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

Impairment of Long-Lived Assets

The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. As of December 31, 2016 and 2015, there was no impairment of the Company’s long-lived assets.

Fair Value of Financial Instruments

Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis (at least annually). Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity, associated with the inputs to the valuation of these assets or liabilities are as follows:

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

•

Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 inputs are unobservable inputs for the asset or liability.

Concentration of Risk

Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties.

Customer Concentration

Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date.

Customers representing greater than 10% of accounts receivable were as follows (in percentages):

	As of December 31,
	2016		2015
Customer A		—		32
Customer E		36		32
Customer F		1		25
Customer H		27		—
Customer I		22		7

Customers representing greater than 10% of total revenues were as follows (in percentages):

	For Year Ended December 31,
	2016		2015
Customer A		—		12
Customer D		30		22
Customer F		—		14
Customer G		21		13
Customer J		11		5

Stock-Based Compensation

The Company recognizes compensation expense related to employee stock purchase plan and the cost of stock-based compensation awards made to employees and directors on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 10 for additional information.

The Company accounts for compensation expense related to stock options granted to non-employees based on the fair values estimated using the Black-Scholes model. Stock options granted to non-employees are re-measured at each reporting date until the award is vested.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

Net Loss per Share

Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.

Revenue Recognition

Revenue is generated through product sales, license agreements, contract research agreements, and government grants. The Company recognizes revenue when the following criteria have been met: persuasive evidence of an arrangement with the customer exists; price and terms of the arrangement are fixed or determinable; delivery of the product has occurred or the service has been performed in accordance with the terms of the arrangement; and collectability is reasonably assured.

For revenue agreements with multiple-element arrangements, such as license and contract agreements, the Company analyzes the arrangements to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. This determination is generally based on whether any deliverable has stand-alone value to the customer. This analysis also establishes a selling price hierarchy for determining how to allocate arrangement consideration to identified units of accounting. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price method and the appropriate revenue recognition principles are applied to each unit. The selling price used for each unit of accounting is based on estimated selling price as neither vendor-specific nor third-party evidence is available. When the Company determines that an arrangement should be accounted for as a single unit of accounting, it must determine the period over which the performance obligations will be performed and revenue will be recognized over the performance period.

Product Revenues

Product revenues consist of sales of our SONOVA products. Product revenues are recognized once passage of title has occurred, contractually specified acceptance criteria have been met, and all other revenue recognition criteria have been met. Shipping and handling costs charged to customers are recorded as revenues and included in cost of product revenues at the time the sale is recognized.

License Revenues

The Company’s license agreements generally include up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments. Upon commercialization of a product utilizing a licensed technology, the Company receives certain value-sharing payments associated with the incremental revenue attributable to the licensed technology.

The Company has determined that, at the inception of each license agreement, there is only one deliverable for the license for, access to, and assistance with the development of the specified intellectual property. The up-front nonrefundable license fees are recognized as revenue proportionally over the development period, which approximates the expected efforts by the Company. The development period is estimated based upon factors such as type of traits, nature of crops and geographies, which are used to establish the initial deferral period. The Company continually reviews such estimates based on progress toward product commercialization and performs a thorough analysis at least annually. If the deferral period estimate changes, the amount of revenue recognized during the period is either accelerated or reversed to reflect the updated deferred balances as of the current period-end, capturing the cumulative effect of the changes. The annual license fees are payable at the end of the annual period and such fees typically are not required to be paid if the agreement is cancelled prior to the due date. Therefore, annual license fees are only recognized when they become due.

The Company’s license agreements generally include contingent milestone payments in the development life cycle of the related technology, such as achievement of specific technological targets, successful results from field trials, filing for approval with regulatory agencies, approvals granted by regulatory agencies and commercial launch of a product utilizing the licensed technology. The Company evaluates whether each milestone is substantive and at risk at the time the agreement is executed. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (i) the entity’s performance to achieve the milestone or (ii) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone; (b) the consideration relates solely to past performance; and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company generally considers non-refundable milestones that the Company expects to be achieved as a result of the Company’s efforts during the period of the Company’s performance obligations under the license agreement to be substantive and recognizes them as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.

Once a product containing one or more of the Company’s traits is commercialized, the Company is entitled to receive a portion of the incremental revenue that the trait generates for its commercial partner. These value-sharing payments will be recorded on the accrual basis when results are reliably measurable, collectability is reasonably assured, and all other revenue recognition criteria are met. None have been received to date.

Contract Research Revenues

Contract research revenues consist of amounts earned from performing contracted research activities for third parties. Activities performed are related to breeding programs or the genetic engineering of plants and are subject to an executed agreement. Generally, fees for research and development activities are recognized as the services are performed over the performance period, as specified in the respective agreements, assuming all other revenue recognition criteria are met.

Similar to the license agreements, under the contract research agreements, once a product containing one or more of the Company’s traits is commercialized, the Company is entitled to receive a portion of the incremental revenue that the trait generates for its commercial partner. These value-sharing payments will be recorded on the accrual basis when results are reliably measurable, collectability is reasonably assured, and all other revenue recognition criteria are met.

Government Grant Revenues

Based on the terms of the government grant, the Company recognizes revenue from payments received from government entities for research and development activities over a contractually defined period. Revenues from government grants are recognized in the period during which the related costs are incurred, provided that the conditions under which the government grants were provided have been met.

Unearned Revenue

The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies.

Research and Development Expenses

Research and development expenses consist of costs incurred in the discovery, development, and testing of the Company’s product candidates. These expenses consist primarily of employee salaries and benefits, including stock-based compensation, fees paid to subcontracted research providers, fees associated with in-licensing technology, royalty agreements, land leased for field trials, chemicals and supplies and other external expenses. These costs are expensed as incurred. Additionally, as disclosed in Note 11, the Company is required from time to time to make certain milestone payments in connection with the development of technologies. These milestone payments are expensed at the time the milestone is achieved and deemed payable.

Recent Accounting Pronouncements

12 Months Ended

Dec. 31, 2016

Accounting Changes And Error Corrections [Abstract]

Recent Accounting Pronouncements

Note 3. Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date, which defers the effective date of ASU No. 2014-09 by one year allowing early adoption as of the original effective date January 1, 2017. The deferral results in the new revenue standard being effective for the Company January 1, 2018. Additional ASUs have been issued to amend or clarify the new guidance in ASC Topic 606 as follows:

•

ASU No. 2016-08 Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) was issued in March 2016. ASU No. 2016-08 requires an entity to determine whether the nature of its promise to provide goods or services to a customer is performed in a principal or agent capacity and to recognize revenue in a gross or net manner based on its principal or agent designation.

•

ASU No. 2016-10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing was issued in April 2016. ASU No. 2016-10 addresses implementation issues identified by the FASB-International Accounting Standards Board Joint Transition Resource Group for Revenue Recognition concerning identifying performance obligations and accounting for licenses of intellectual property.

•

ASU No. 2016-12 Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients was issued in May 2016. ASU No. 2016-12 amends the new revenue recognition standard to clarify the guidance on assessing collectability, measuring noncash consideration, presenting sales taxes and certain transition matters.

•

ASU No. 2016-20 Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers was issued in December 2016. ASU No. 2016-20 provides additional clarification on 13 issues or corrects unintended application of FASB Accounting Standards Codification (Topic 606).

The standard permits the use of either the retrospective or cumulative effect transition method. The initial analysis identifying areas that will be impacted by the new guidance is substantially complete, and the Company is currently analyzing the potential impacts to its consolidated financial statements and related disclosures. The Company believes there may be a potential material impact to license revenue with the adoption of the new revenue recognition guidance. Based on our ongoing review, we expect to adopt the requirements of the new standard in the first quarter of 2018 using the modified retrospective method. The Company has not concluded on the effect of the aforementioned updates on its consolidated financial statements.

In August 2014, The FASB issued ASU No. 2014-05, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how to disclose going-concern uncertainties in the consolidated financial statements. The new standard requires management to preform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the consolidated financial statements are issued. An entity must provide certain disclosure if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The update applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption is permitted. The Company is still evaluating the potential impact to its consolidated financial statements with the adoption of this ASU, but it does not anticipate a material change. However, it will be required to evaluate and determine if further disclosure is necessary at each balance sheet date.

In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. The amendments in this update changes the guidance with respect to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. All legal entities are subject to reevaluation under the revised consolidation model. The standard affects the following areas: (1) limited partnerships and similar legal entities, (2) evaluating fees paid to a decision maker or a service provider as a variable interest, (3) the effect of fee arrangements on the primary beneficiary determination, (4) the effect of related parties on the primary beneficiary determination, and (5) certain investment funds. It does not affect the general order in which the consolidation models are applied or the general approach for applying the VIE model. The standard is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The standard permits the use of modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or retrospectively. The Company had selected the modified retrospective approach for the annual reporting period of December 31, 2016. The adoption of this guidance did not have an impact on the consolidated financial statements or related disclosures.

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in this update impacts classification, additional fair value measurement, impairment assessment of equity investments and current required disclosures. This standard is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted if the entity meets certain early application guidance. The Company is evaluating the impact of the adoption of ASU No. 2016-01 on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Based on the new standard, lessees would recognize lease assets and lease liabilities for those leases classified as operating leases under previous GAAP. The standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application is permitted. The Company is currently evaluating the impact of the adoption of ASU No. 2016-02 on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. The Company has early adopted ASU No. 2016-09 in the fourth quarter of 2016 and elected to continue to estimate its forfeiture rates on stock-based compensation. The adoption of ASU No. 2016-09 did not have a significant impact on our financial statements or disclosure. The impact to the Company’s year-end financial statements, includes the establishment of a deferred tax asset (“DTA”) for the off-balance sheet net operating losses (“NOLs”) generated as a result of excess share based compensation deductions that have not yet been realized. Given the Company’s valuation allowance position, there is no impact to opening retained earnings as a result of the adoption of the ASU. On a prospective basis, the net shortfall/windfall will be recorded directly to the income tax provision.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is evaluating the impact of the adoption of ASU No. 2016-13 on its consolidated financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The amendments address cash flow issues such as debt prepayment or debt extinguishment costs and zero-coupon debt instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. The amendments are to be applied using a retrospective transition method to each period presented. If it is impractical to retrospectively apply, it can be applied prospectively as of the earliest date practicable. The Company is evaluating the impact of the adoption of ASU No. 2016-15 on its consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

Property and Equipment, Net

12 Months Ended

Dec. 31, 2016

Property Plant And Equipment [Abstract]

Property and Equipment, Net

Note 4. Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	As of December 31,
	2016			2015
Laboratory equipment	$	2,632		$	2,528
Software and computer equipment		449			441
Furniture and fixtures		153			153
Vehicles		204			204
Leasehold improvements		1,991			1,900
Assets under construction		20			18
Property and equipment, gross		5,449			5,244
Less accumulated depreciation and amortization		(4,941	)		(4,659	)
Property and equipment, net	$	508		$	585

Depreciation and amortization expense is $304,000 and $294,000 for the years ended December 31, 2016 and 2015, respectively.

Investments and Fair Value Measurements

12 Months Ended

Dec. 31, 2016

Investments And Fair Value Measurements [Abstract]

Investments and Fair Value Measurements

Note 5. Investments and Fair Value Measurements

Available-for-Sale Investments

The Company classified short-term and long-term investments as “available-for-sale.” Investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses, net of taxes, are included in accumulated other comprehensive income (loss), which is reflected as a separate component of stockholder’s equity (deficit) in the Consolidated Balance Sheets. Gains and losses are recognized when realized in the Consolidated Statements of Operations and Comprehensive Loss.

The Company’s investments in fixed income securities consisted of the following as of December 31, 2016:

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Assets at Fair Value
Cash equivalents:
Money market funds	$	1,549	$	—	$	—		$	1,549
Short-term investments:
Certificates of Deposit		3,049		—		(2	)		3,047
Commercial paper		21,248		—		—			21,248
U.S. government securities		19,267		—		(9	)		19,258
U.S. government agency securities		5,000		—		(6	)		4,994
Long-term investments:
U.S. government securities		2,500		—		(2	)		2,498
Total Assets at Fair Value	$	52,613	$	—	$	(19	)	$	52,594

The Company’s investments in fixed income securities consisted of the following as of December 31, 2015:

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Assets at Fair Value
Cash equivalents:
Money market funds	$	12,799	$	—	$	—		$	12,799
Commercial paper		5,949		—		—			5,949
U.S. government agency securities		3,049		—		—			3,049
Short-term investments:
Certificates of Deposit		3,374		—		—			3,374
Commercial paper		3,598		—		—			3,598
U.S. government securities		13,678		—		(30	)		13,648
U.S. government agency securities		5,653		1		(4	)		5,650
Long-term investments:
Certificates of Deposit		3,049		—		—			3,049
U.S. government securities		11,780		—		(52	)		11,728
U.S. government agency securities		5,001		—		(30	)		4,971
Total Assets at Fair Value	$	67,930	$	1	$	(116	)	$	67,815

The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of December 31, 2016. The unrealized gains and losses amounts above are included in AOCI as of December 31, 2016. All long-term investments will mature in 2018.

As of December 31, 2016, for fixed income securities that were in unrealized loss positions, the Company has determined that (i) it does not have the intent to sell any of these investments, and (ii) it is not more likely than not that it will be required to sell any of these investments before recovery of the entire amortized cost basis. The Company anticipates that it will recover the entire amortized cost basis of such fixed income securities and has determined that no other-than-temporary impairments associated with credit losses were required to be recognized during the year ended December 31, 2016.

Fair Value Measurement

The fair value of the available-for-sale investments at December 31, 2016 were as follows:

	Fair Value Measurements at December 31, 2016
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	1,549	$	—	$	—	$	1,549
Short-term investments:
Certificates of Deposit		—		3,047		—		3,047
Commercial paper		—		21,248		—		21,248
U.S. government securities		19,258		—		—		19,258
U.S. government agency securities		—		4,994		—		4,994
Long-term investments:
U.S. government securities		2,498		—		—		2,498
Total Assets at Fair Value	$	23,305	$	29,289	$	—	$	52,594

The fair value of the available-for-sale investments at December 31, 2015 were as follows:

	Fair Value Measurements at December 31, 2015
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	12,799	$	—	$	—	$	12,799
Commercial paper		—		5,949		—		5,949
U.S. government agency securities		—		3,049		—		3,049
Short-term investments:
Certificates of Deposit		—		3,374		—		3,374
Commercial paper		—		3,598		—		3,598
U.S. government securities		13,648		—		—		13,648
U.S. government agency securities		—		5,650		—		5,650
Long-term investments:
Certificates of Deposit		—		3,049		—		3,049
U.S. government securities		11,728		—		—		11,728
U.S. government agency securities		—		4,971		—		4,971
Total Assets at Fair Value	$	38,175	$	29,640	$	—	$	67,815

The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2016 or 2015. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and debt instruments. For accounts receivable, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2016 and 2015 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The carrying values of long-term debt, approximate fair value and is principally measured using Level 2 inputs based on quoted market prices or pricing models using current market rates.

The Company’s Level 3 liabilities, which were measured and recorded on a recurring basis, consist of derivative liabilities related to the convertible promissory note. The following table sets forth a summary of the changes in the fair value and other adjustments of these derivative liabilities (in thousands):

	Year Ended December 31,
	2016		2015
Beginning balance	$	—	$	1,580
Change in fair value and other adjustments		—		9
Derecognition of derivative liabilities upon debt extinguishment		—		(1,589	)
Ending balance	$	—	$	—

Investment in Unconsolidated Entity

12 Months Ended

Dec. 31, 2016

Equity Method Investments And Joint Ventures [Abstract]

Investment in Unconsolidated Entity

Note 6. Investment in Unconsolidated Entity

Limagrain Cereal Seeds LLC

The Company owns a 35% ownership position in Limagrain Cereal Seeds LLC (“LCS”). The remaining 65% of LCS is owned by Vilmorin & Cie (“Limagrain”), a major global producer and marketer of field crop and vegetable seeds, through its wholly owned subsidiary, Vilmorin USA (“VUSA”). LCS improves and develops new wheat and barley varieties utilizing genetic and breeding resources, as well as advanced technologies from Limagrain and the Company. Funding for LCS comes from an initial pro rata equity investment from each partner and with subsequent financing in the form of debt from VUSA. As of December 31, 2016, the debt balance was $25.0 million with a maturity date of April 15, 2017. While it is the Company’s expectation that VUSA will provide LCS with additional debt financing and extend maturity for payment as needed, should additional capital in the form of equity be necessary to support the operations of LCS, the Company has the option to fund its pro rata share of such cash or elect to have its ownership percentage diluted. As of December 31, 2016 and 2015, the Company’s investment in LCS has been reduced to $0 as a result of its equity method loss recognition.

Summarized condensed financial information related to the unconsolidated entity, accounted for using the equity method is as follows (in thousands):

	As of and for the year ended December 31,
	2016			2015
Assets:
Current assets	$	2,963		$	2,104
Non-current assets		9,776			9,864
Total assets		12,739			11,968
Liabilities and equity:
Current liabilities		26,992			20,807
Equity of Arcadia Biosciences, Inc.(1)		(4,989	)		(3,002	)
Equity of VUSA		(9,264	)		(5,837	)
Total liabilities and equity	$	12,739		$	11,968
Revenue	$	3,635		$	3,630
Gross profit		1,594			1,328
Loss from continuing operations		(5,268	)		(5,509	)
Net loss (2)		(5,413	)		(5,741	)

(1)	Effective June 2014, the investment balance has been reduced to $0.

(2)	As the Company’ investment balance has been reduced to $0 in 2014, the Company’s share of the pretax loss is $0 for the years ended December 31, 2016 and 2015.

Variable Interest Entity	12 Months Ended
Variable Interest Entity	Dec. 31, 2016
Equity Method Investments And Joint Ventures [Abstract]
Variable Interest Entity	Note 7. Variable Interest Entity In February 2012, the Company formed Verdeca LLC, which is jointly owned with Bioceres, Inc. ("Bioceres"), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development company owned by approximately 250 shareholders, including some of South America’s largest soybean growers. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. Both the Company and Bioceres incur expenses in support of specific activities agreed, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period. The Company determined that its commitment to purchase common stock in Bioceres, S.A. as a means to provide capital to Verdeca resulted in a de facto agency relationship between the Company and Bioceres. The Company considers qualitative factors in assessing the primary beneficiary which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is the primary beneficiary of Verdeca. As a result of the agreement to fund future contributions by Bioceres, Inc., the Company purchased common stock of Bioceres, S.A. in the aggregate amount of $2.0 million between January 2013 and August 2014. The Company’s maximum commitment to purchase stock in Bioceres, S.A. under the original funding agreement amounted to $2.0 million for 2014 and $1.2 million for 2015. In September 2014, the Company and Bioceres, S.A. entered into an agreement to reduce the annual commitment for 2014 to $500,000 and to eliminate the 2015 commitment. In consideration for these amendments, the Company surrendered 1,832 shares of Bioceres, S.A. held by the Company. The Company recorded an expense of $1.5 million related to this agreement in 2014. In addition, the Company had a right to require Bioceres, S.A. to repurchase any shares of common stock then owned by the Company upon the occurrence of certain events specified in the agreement, and similarly, Bioceres, S.A. had the right to require the Company to sell back any shares of common stock owned by the Company under certain circumstances. The Company entered into a subcontracted research agreement in 2015 with Bioceres S.A. and Bioceres Semillas, S.A., a subsidiary of Bioceres S.A. Per the agreement, the Company could pay for these services with a combination of cash and Bioceres S.A. shares. As of December 31, 2015, the liability for the aforementioned research agreement was settled with $205,000 of cash and the remaining 632 Bioceres S.A. shares with a fair value of $500,000 held by the Company, thus reducing the cost investment on the Consolidated Balance Sheet to $0. Under the terms of the joint development agreement, the Company has incurred direct expenses and allocated overhead in the amount of $416,000 and $1.3 million for the years ended December 31, 2016 and 2015, respectively.

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2016

Payables And Accruals [Abstract]

Accounts Payable and Accrued Expenses

Note 8. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands):

	As of December 31,
	2016		2015
Accounts payable—trade	$	222	$	424
Payroll and benefits		1,331		1,050
Research and development		182		323
Royalty fees due to unrelated parties		170		157
Accrued interest on notes payable		98		9
Consulting		29		152
Rent and utilities		85		77
Legal		45		57
Accrued withholding taxes		—		24
Other		197		150
Total accounts payable and accrued expenses	$	2,359	$	2,423

Exit or Disposal Activities

As of December 2016, the Company completed a comprehensive strategic review of its technology programs, pipeline, partner program progress, competitive landscape and market conditions, which resulted in the decision to realign its organizational capabilities to best support the Company’s near term product commercialization needs and preserve cash. As a result, a number of personnel changes were made, including the elimination of 23 positions. The severance costs associated with this reduction in force (RIF) were $192,000 for one-time employee termination benefits, and $224,000 in severance costs in connection with an executive employment contract, both of which, are recorded in Selling, General, and Administrative expense for the year ended December 31, 2016. A portion of the one-time employee termination benefits was paid out in December 2016 and the remaining severance amount of $389,000 was accrued under payroll and benefits as of December 31, 2016. Additionally, the Company has commenced closure of its Seattle office, which it expects will be completed by March 2017. Other than the aforementioned liability, the Company has no other associated exit or disposal costs pertaining to the year ended December 31, 2016.

Long-Term Debt and Other Financing Arrangements

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Long-Term Debt and Other Financing Arrangements

Note 9. Long-Term Debt and Other Financing Arrangements

Longterm debt consisted of the following (in thousands):

	December 31, 2016		December 31, 2015
Notes payable	$	25,127	$	24,930
Total	$	25,127	$	24,930
Less current portion		—		—
Long-term portion	$	25,127	$	24,930

Term Note, Related Party

In July 2012, a 36month $8.0 million term note was executed with Moral Compass Corporation (“MCC”), the Company’s largest stockholder, and was subordinate to existing promissory notes and convertible promissory notes. This term note, including the principal balance of $8.0 million and accrued interest and prepayment fee of $148,000 was paid in full in April 2015. A prepayment fee of $80,000 was recorded as a loss on extinguishment of debt in 2015.

Promissory Notes

Promissory notes were executed with an unrelated party in August 2013 and November 2013 in the amounts of $2.0 million and $1.1 million, respectively. These notes, including the aggregate outstanding principal balance of $1.6 million and accrued interest and prepayment fee of $44,000, were paid in full in April 2015. A prepayment fee of $37,000 was recorded as a loss on extinguishment of debt in 2015.

Convertible Promissory Notes

Two notes and a warrant purchase agreement (“Convertible Promissory Notes”) were executed in September 2013 and December 2013 with Mahyco International, an affiliate of Maharashtra Hybrid Seeds Company Ltd. (“Mahyco”), which is a licensee of the Company’s technologies. The notes under this agreement were issued in the amounts of $500,000 in September 2013 and $4.5 million in December 2013. The interest rate on the notes was prime plus 2%, compounded monthly over the course of the fiveyear terms ending September and December 2018, and was payable in full on the maturity dates. At any time during the term, the lender could convert all or part of the outstanding balance of the notes (including principal and accrued but unpaid interest) into common stock of the Company at $16.52 per share through December 2016 and at 90% of the most recent offering thereafter.

At its option, Mahyco International could offset future fee payments due from Mahyco to the Company against the outstanding balance of the notes (including principal and accrued but unpaid interest). Mahyco International had the right to demand immediate settlement of a portion of the outstanding balance of the convertible promissory notes, subject to mutual agreement by the Company. The Company recorded a derivative liability for the initial fair value of the settlement obligation. In addition, the lender had the right, at its option, to place another $5.0 million of convertible debt with the Company during the fiveyear term. The Company recorded an additional derivative liability for the initial fair value of the Company’s obligation to issue the additional $5.0 million of convertible promissory notes. Changes in the fair value of the derivative liabilities were recorded to other income (expense), net in the Consolidated Statement of Operations and Comprehensive Loss.

In conjunction with the convertible promissory notes, the Company issued to the lender a warrant to purchase 75,666 shares of common stock at an exercise price of $16.52. The warrant was issued in December 2013, vested immediately and remains exercisable throughout the original fiveyear term. The Company allocated the gross proceeds from the notes to the derivative liabilities based on their initial fair values and the remainder of the proceeds to the convertible promissory note and warrants on a relative fair value basis. The amount allocated to the common stock warrant was recorded as a debt discount to be amortized as interest expense over the estimated term of the loan agreement using the effective interest rate method. The Company recognized interest expense related to the convertible promissory note of $747,000 for the year ended December 31, 2015. Of the total interest expense recognized, $536,000 was related to the debt discount for the year ended December 31, 2015. In March 2015, the parties amended the warrant to clarify certain terms relating to expiration. The Company accounted for the amendment as a modification with the incremental increase in fair value of $197,000 as of the amendment date, which was accounted for as deemed dividends to the warrant holder.

Term Loans

In April 2015, the Company entered into a loan and security agreement with an unrelated party, under which the Company incurred an aggregate principal amount of $20.0 million in term loan borrowings (the “Term Loans”), proceeds of which were used to repay existing debt with MCC and an unrelated party as described above. Under this loan agreement, interest on the Term Loans accrued at a rate per annum equal to the greater of (i) 9.0% and (ii) a fluctuating rate of interest equal to threemonth LIBOR as in effect from time to time plus 8.74%. The Company was required to make interestonly payments under this agreement from the drawdown dates through April 30, 2016, subject to certain conditions for extension to October 31, 2016. After this date, equal monthly payments of principal and interest would have been required so that all outstanding principal amounts and accrued interest would have been repaid by November 1, 2018. This agreement provided for a right of prepayment with associated prepayment fees and an additional end-of-term payment of $600,000 due upon maturity or when the Term Loans are prepaid in whole or in part to the lenders.

As part of the Term Loans, the Company also issued the lenders warrants to purchase 1,503,760 shares of its common stock at an exercise price of $5.32 per share, which were only exercisable in the event that an IPO was not completed prior to September 30, 2015 and would have remained exercisable until November 1, 2018. The Company initially recorded $356,000 for the fair value of the warrants as a liability in the Consolidated Balance Sheets, which was subject to subsequent remeasurement for changes in fair value until exercise or expiration. In addition, the Company concluded that the interest rate adjustment upon nonoccurrence of an IPO was an embedded derivative and recorded $81,000 for the fair value of the embedded derivative as a liability, which was subject to subsequent remeasurement for changes in fair value until exercise or expiration. The proceeds received under the Term Loans, less fees paid to the lender of $290,000, were allocated to the warrant liability and the embedded derivative liability based on their initial fair values with the residual amount recorded as notes payable. The resulting debt discount was to be amortized as interest expense over the term of the Term Loans using the effective interest method. The interest expense related to the debt discount was $301,000 for the year ended December 31, 2015.In May 2015, upon the completion of the IPO, the warrants were terminated and the right to adjust the interest rate upon nonoccurrence of an IPO was relinquished. As such, the Company released the initial fair value of the warrants and the embedded derivative of $437,000 to other income. The Company recognized interest expense inclusive of the debt discount related to the combined Term Loans of $1.5 million for the year ended December 31, 2015.

In July 2015, the Company amended the Term Loans to include collateral of certain intellectual property rights in exchange for a waiver of the Company’s obligation to obtain a subordination agreement from Mahyco International with respect to the indebtedness the Company owed to them. In an event of default, the lenders could have accelerated and declared to be immediately due and payable the outstanding principal amount of the Term Loans and the Company’s other payment obligations under the agreement. In the case of a bankruptcy or insolvency event of default, the outstanding principal amount of the Term Loans and the Company’s other payment obligations under the loan agreement automatically would have accelerated and become due and payable. In addition, if an event of default occurred and continued under the loan agreement, the lenders could have exercised certain additional secured creditor remedies against the Company and against the assets that secured the Company’s obligations under the agreement.

In December 2015, the Company entered into a new loan and security agreement with Silicon Valley Bank (the “Bank”) providing for a senior secured term loan facility in the amount of $25.0 million. Proceeds were used by the Company to repay all existing debt including the Term Loans’ principal balance of $20.0 million and related accrued interest, prepayment and other fees in the amount of $1.3 million and the Convertible Promissory Notes’ principal balance of $3.7 million and associated accrued interest of $154,000. The Term Loans’ prepayment and end of term fees of $1.2 million were recorded as a loss on extinguishment of debt, along with the $427,000 unamortized debt discount and $58,000 of deferred loan issuance fees. In addition, Mahyco International’s option to place another $5.0 million of convertible debt was surrendered with the repayment and the related derivative liabilities totaling $1.6 million were released and recorded as a gain on extinguishment of debt in 2015.

Under this existing loan and security agreement, interest accrues at a floating rate per annual rate equal to nine tenths of one percentage point (0.90%) above the prime rate published from time to time in The Wall Street Journal. The agreement requires the Company to make monthly interest-only payments through December 2017. After this date, the Company is required to make thirty-six (36) equal monthly installments of principal, plus accrued interest. The Company’s final payment, due on the maturity date of December 1, 2020, shall include all outstanding principal and accrued and unpaid interest plus a final payment equal to $600,000. In the event the loan is repaid prior to its maturity, a prepayment fee is due equal to 3% of the outstanding principal amount if prepayment occurs after December 29, 2016 but on or before December 29, 2017, and 1% of the outstanding principal amount if the prepayment occurs after December 29, 2017. The loan had been recorded on the Consolidated Balance Sheet as of December 31, 2015, net of issuance fees.

This loan and security agreement contains customary events of default and covenants, including a financial covenant that requires the Company to maintain either a liquidity ratio (defined as the ratio of the Company’s cash, cash equivalents and net accounts receivable to the Company’s obligation owed to the Bank) of at least 1.4:1.0, or to cash collateralize 100% of the Company’s obligations to the Bank. The Company’s obligations to the Bank are secured by substantially all of the Company’s assets, excluding intellectual property.

The Company recognized interest expense related to this agreement of $1.3 million for the year ended December 31, 2016. Of the total interest recognized, $198,000 was related to the debt discount for the year ended December 31, 2016.

Minimum principal payments on the Company’s outstanding debt related to the existing term loan as of December 31, 2016 are as follows (in thousands):

	December 31, 2016
2017	$	—
2018		8,333
2019		8,333
2020		8,334
Total	$	25,000

Loss on Debt Extinguishment

The Company recognized a loss on debt extinguishment of $0 and $230,000 for the years ended December 31, 2016 and December 31, 2015, respectively. The loss was comprised of prepayment fees, deferred issuance fees and the release of derivative liabilities related to repaid debts noted above.

Stock-Based Compensation

12 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

Note 10. Stock-Based Compensation

Stock Incentive Plans

The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”).

In February 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under the terms and provisions established by the Board of Directors. The Company granted options under the 2006 Plan until May 2015, at which time it was terminated with respect to future awards, although it continues to govern the terms of options that remain outstanding under the plan. Certain options vested upon completion of the IPO and the remaining unvested options vest over original service periods between two-and-a-quarter and four years.

In May 2015, the 2015 Plan became effective upon the IPO and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,087,729 shares of common stock reserved for future issuance, which included 212,729 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016. In addition, shares subject to awards under the 2006 Plan that are forfeited or terminated will be added to the 2015 Plan.

The 2015 Plan provides for the grant of incentive stock options (“ISOs”), within the meaning of Section 422 of the Code, to our employees and for the grant of nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock, restricted stock units, performance units, and performance shares to our employees, directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at date of grant. Options granted generally vest over a four-year period, with 25% vesting at the end of one year and the remaining vesting monthly thereafter. Options granted generally are exercisable for 10 years, the maximum contractual period.

As of December 31, 2016, a total of 5,223,245 shares of common stock were reserved for issuance under the 2015 Plan, of which 3,522,999 shares of common stock are available for future grant. As of December 31, 2016, a total of 2,878,536 and 1,700,246 options are outstanding under the 2006 and 2015 Plans, respectively.

The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share):

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2014		3,759,839		$	3.00	$	12,499
Options granted		352,494			7.30
Options exercised		(609,066	)		0.59
Options cancelled and forfeited		(75,758	)		7.33
Outstanding — Balance at December 31, 2015		3,427,509		$	3.76	$	3,707
Options granted		1,799,395			5.17
Options exercised		(228,141	)		1.18
Options cancelled and forfeited		(419,981	)		4.49
Outstanding — Balance at December 31, 2016		4,578,782			4.38	$	—
Vested and expected to vest — December 31, 2016		4,561,042			4.37	$	—
Exercisable —December 31, 2016		2,804,796		$	3.65	$	—

Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by the Board of Directors for each of the respective periods. The intrinsic value of options exercised was $0 and $1.5 million for the years ended December 31, 2016 and 2015, respectively.

At December 31, 2016 and 2015, there were no expired options, and the total fair value of shares vested during the years were $283,000 and $730,000, respectively.

As of December 31, 2016, there was $1.7 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 3.12 years.

In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

Expected Term—The expected term is the estimated period of time outstanding for stock options granted and was estimated based on historical, as well as anticipated future, exercise activity.

Expected Volatility—Since the Company was privately held and does not have a long trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. When selecting comparable publicly traded biotechnology companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

Risk-Free Interest Rate—The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted.

Expected Dividend—The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders.

The fair value of stock option awards to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption:

	Year Ended December 31,
Assumptions	2016		2015
Expected term (years)	5.40 - 6.25			5.52
Expected volatility	87.80% - 91.40%			100%
Risk-free interest rate	1.17% - 1.54%			1.61%
Expected dividend yield		—		—

The weighted- average, estimated grant-date fair value of employee stock options granted during the years ended December 31, 2016 and 2015 was $1.13 and $4.64, respectively. The Company recognized $1.0 million and $1.3 million of compensation expense for stock options to employees and nonemployees for the years ended December 31, 2016 and 2015, respectively.

Employee Stock Purchase Plan

In May 2015, the Company’s 2015 Employee Stock Purchase Plan (“ESPP”) was introduced. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. The initial number of shares of common stock reserved for issuance under the ESPP is 625,000, and the ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of December 31, 2016, 75,342 shares had been issued under the ESPP. The Company recorded $80,000 and $69,000 of ESPP related compensation expense for the years ended December 31, 2016 and 2015, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Commitment and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11. Commitments and Contingencies

Leases

The Company leases office and laboratory space, greenhouse space, grain storage bins, warehouse space, and equipment under operating lease agreements having initial lease terms ranging from three to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. Future minimum payments under non-cancelable operating leases in effect as of December 31, 2016, are presented below (in thousands):

Years Ending December 31,	Amounts
2017	$	782
2018		334
2019		5
Total future minimum payments under non- cancelable operating leases	$	1,121

Rent expense under all operating leases totaled $1.3 million for both years ended December 31, 2016 and 2015.

Legal Matters

From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. As of December 31, 2016 and 2015, the Company was not involved in any legal proceedings.

Contingent Liability Related to the Anawah Acquisition

On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. ("Anawah" or "Sellers"), to purchase the Sellers’ food and agricultural research company through a stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs and, as a result, reduced the contingent liability to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. As of December 31, 2016, the Company continues to pursue a total of three development programs using this technology and believe that the contingent liability is probable, thus $3.0 million remains on the Consolidated Balance Sheet as an other noncurrent liability.

Contracts

The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable.

The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements will be due.

Royalties due to both related and unrelated parties on license revenue accrued as of December 31, 2016 and 2015 were $201,000 and $177,000, respectively. Royalties are included within research and development on the Consolidated Statements of Operations and Comprehensive Loss.

Milestone payments are contingent upon the successful development or implementation of various technologies. Payments for milestones yet to be achieved totaled $2.0 million for both years ended December 31, 2016 and 2015. The timing of the payments is not determinable at this time pending research and development currently in progress; however, no significant payments were made during the years ended December 31, 2016 and 2015.

The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Note 12. Income Taxes

The components of loss before income taxes are as follows:

	Year Ended December 31,
	2016			2015
Domestic	$	(19,599	)	$	(17,930	)
Foreign		—			—
Loss before income taxes	$	(19,599	)	$	(17,930	)

The components of the provision for income taxes for the years ended December 31, 2016 and 2015 are as follows (in thousands):

	Year Ended December 31,
	2016		2015
Current:
Federal	$	—	$	—
State		1		2
Foreign		24		24
Total current tax expense		25		26
Deferred:
Federal		—		—
State		—		—
Foreign		—		—
Total deferred tax benefit		—		—
Total tax expense	$	25	$	26

The Company operates in only one federal jurisdiction, the United States. The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	Year Ended December 31,
	2016			2015
Expected income tax provision at the federal statutory rate		34.0	%		34.0	%
State taxes, net of federal benefit		4.7	%		4.5	%
Change in valuation allowance		(37.8	)%		(36.8	)%
Nondeductible expenses		(0.9	)%		(1.8	)%
Withholding taxes		(0.1	)%		(0.1	)%
Income tax provision		(0.1	)%		(0.2	)%

The total income tax expense for the years ended December 31, 2016 and 2015 was $25,000 and $26,000, respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States.

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, net operating loss carryforwards (“NOLs”) and other tax credits. Significant components of the Company’s deferred tax assets are as follows (in thousands):

	As of December 31,
	2016			2015
Deferred tax assets:
Net operating loss carryforwards	$	49,593		$	41,807
Unearned revenue		1,501			1,421
Stock-based compensation		2,861			2,485
Accrued payroll and benefits		215			226
Research and development credits		143			106
Capital loss carryover		13			16
Fixed asset basis difference		191			192
Inventory reserve		1,110			912
Charitable contributions		5			7
Total deferred tax assets		55,632			47,172
Less valuation allowance		(55,632	)		(47,172	)
Net deferred tax assets	$	—		$	—

Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been offset by a valuation allowance. The net valuation allowance increased by $8.5 million and $6.6 million during the years ended December 31, 2016 and 2015, respectively. Refer to Note 3 for a description of the impact to the DTA by adopting ASU No. 2016-09 Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.

At December 31, 2016, the Company had federal and state NOLs aggregating approximately $136.2 million and $100.3 million, respectively. At December 31, 2016, the utilization of a portion of our NOLs is subject to an annual limitation under Section 382 of the Internal Revenue Code (IRC). Of the $136.2 million generated, $7.2 million will not be available to be utilized within the carryforward period. If not utilized, these federal NOLs will begin to expire in 2020 and these state NOLs will begin to expire in 2017. The Company continues to evaluate IRC Section 382, which may limit NOLs generated in future years.

The Company evaluates deferred tax assets, including the benefit from NOLs, to determine if a valuation allowance is required. Such evaluation is based on consideration of all available evidence using a “more likely than not” standard with significant weight being given to evidence that can be objectively verified. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses; forecasts of future profitability; the length of statutory carryforward periods; the Company’s experience with operating losses; and tax-planning alternatives. The significant piece of objective negative evidence evaluated was the cumulative loss incurred over the year ended December 31, 2016. Given this evidence and the expectation to incur operating losses in the foreseeable future, a full valuation allowance has been recorded against net deferred tax asset. The Company will continue to maintain a full valuation allowance against the entire amount of its net deferred tax asset, until such time as the Company has determined that the weight of the objectively verifiable positive evidence exceeds that of the negative evidence and it is likely that the Company will be able to utilize all of its net deferred tax asset relating to its federal and state NOL carryforwards. Although the Company has established a full valuation allowance on its net deferred tax asset, it has not forfeited the right to carryforward tax losses up to 20 years and applies such tax losses against taxable income in such years, thereby reducing its future tax obligations. The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2016, the Company’s tax years for 2006 through 2016 are generally subject to examination by the tax authorities. The years are open back to 2000 to the extent the NOLs being carried forward were generated then.

The Company applies the provisions of ASC 740 related to accounting for uncertain tax positions and concluded there were no such positions associated with the Company requiring accrual of a liability. As of December 31, 2016, the Company has not accrued for any such positions. The Company is currently not under audit for federal or state tax purposes. The Company does not expect a significant change to occur within the next 12 months.

Retirement Benefits	12 Months Ended
Retirement Benefits	Dec. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Retirement Benefits	Note 13. Retirement Benefits The Company has a 401(k) retirement plan (the “Plan”) available for participation by all regular full-time employees who have completed three months of service with the Company. The Company established the Plan in 2008. The Plan provides for a discretionary matching contribution equal to 50% of the amount of the employee’s salary deduction, not to exceed 3% of the salary per employee. Highly compensated employees are excluded from receiving any discretionary matching contribution. Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment. The Company has the option to make discretionary matching contributions. The Company did not make discretionary matching contributions during the years ended December 31, 2016 and 2015.

Segment Reporting

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment and Geographic Information

Note 14. Segment and Geographic Information

Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company’s chief operating decision maker.

Revenues based on the location of the customers, are as follows (in thousands):

	Year Ended December 31,
	2016			2015
United States	$	2,715		$	3,880
India (1)		(100	)		658
Africa		353			293
United Arab Emirates		—			200
Belgium		—			121
France		18			91
Canada		202			75
Other		—			96
Total	$	3,188		$	5,414

(1)	The negative amount is due to the change in estimated commercialization dates in 2016, which impacted the timing of revenue recognition.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Net Loss per Share

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Net Loss per Share

Note 15. Net Loss per Share

Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weightedaverage number of common shares outstanding during the period and excludes any dilutive effects of stockbased awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants and conversion of convertible promissory notes, redeemable convertible preferred stock and convertible preferred stock. As the Company had net losses for the years ended December 31, 2016 and 2015, all potentially dilutive common shares were determined to be antidilutive.

Securities that were not included in the diluted per share calculations because they would be antidilutive were as follows (in shares):

	Year Ended December 31,
	2016		2015
Options to purchase common stock		4,578,782		3,427,509
Warrants to purchase common stock		1,336,894		1,336,894
Total		5,915,676		4,764,403

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 16. Related Party Transactions The Company’s related parties include MCC, Blue Horse Labs, Inc. (“BHL”), and Limagrain. As of December 31, 2015, BHL is deemed a related party as a result of its existing contractual relationship with the Company and because a Director of the Company also served as the Treasurer of BHL and as an Officer and Director of MCC, the Company’s controlling stockholder. Upon the resignation of the Director in November 2016, BHL remains an affiliate of the Company as of December 31, 2016. Transactions with related parties are reflected in the consolidated financial statements under amounts due to related parties and notes payable to related party. Outlined below are details of agreements between the Company and its related parties: A term note was executed with MCC in July 2012 for $8.0 million (see Note 9). This note was repaid in full in April 2015. Under a license agreement executed in 2003 and amended in 2009, BHL receives a singledigit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding from BHL. Royalty fees due to BHL were $30,000 and $19,000 as of December 31, 2016 and December 31, 2015, respectively, and are included in the Consolidated Balance Sheets as amounts due to related parties. License agreements were executed with Limagrain, a stockholder of the Company, in September 2009 and February 2011. The agreements license certain of the Company’s traits to Limagrain and include upfront license fees, annual license fees, milestone fees and valuesharing payments. Limagrain was subject to Item 404 of Regulation S-K – Transactions with Related Person, Promoters and Certain Control Person until the IPO in May 2015, at which time its ownership percentage fell below the 5% threshold. The Company recognized $91,000 of revenue under these agreements for the year ended December 31, 2015.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Organization

Arcadia Biosciences, Inc. (the "Company"), was incorporated in the state of Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Seattle, Washington; Phoenix, Arizona; and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015.

The Company is an agricultural biotechnology trait company engaged in the development of traits that improve food, feed and fiber crops, and enhance the value of the resulting agricultural products. Its traits are focused on high-value enhancements that increase crop yields by enabling plants to more efficiently manage environmental and nutrient stresses, and that enhance the quality and value of agricultural products.

In February 2012, the Company formed Verdeca LLC ("Verdeca", see Note 7), which is jointly owned with Bioceres, Inc. ("Bioceres"), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres S.A. is an agricultural investment and development cooperative. Verdeca, which is consolidated by the Company, was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies.

Reverse Stock Split

In April 2015, the Company’s board of directors approved an amended and restated certificate of incorporation to effect a reverse split on the Company’s issued and outstanding common stock at a one-for-four ratio. In May 2015, the Company’s stockholders approved the certificate of amendment, which the Company filed on May 8, 2015 with the Secretary of State of Delaware to effect the reverse split. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statement have been retroactively adjusted to reflect the reverse stock split for all periods presented. The consolidated financial statements have also been retroactively adjusted to reflect a proportional adjustment for the conversion ratio for each series of redeemable convertible preferred stock and convertible preferred stock.

Initial Public Offering

In May 2015, the Company completed an initial public offering (“IPO”) and subsequently in June 2015, the Company completed the sale of additional shares upon exercise of the underwriters’ over-allotment option. In connection with the IPO, the Company issued 8,528,306 shares of common stock at $8.00 per share, which raised $58.4 million in proceeds, net of underwriting discounts and commissions of $4.8 million and offering expenses of $5.0 million. At the closing of the IPO, all of the outstanding shares of convertible preferred stock and redeemable convertible preferred stock were automatically converted into 32,972,793 shares of common stock. Following the IPO, there were no shares of preferred stock outstanding.

In connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation to change the authorized capital stock to 400,000,000 shares designated as common stock and 20,000,000 shares designated as preferred stock, all with a par value of $0.001 per share.

Basis of Presentation and Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Investments in Equity and Debt Securities

Other-than-Temporary Impairments on Investment

Accounts Receivable

SONOVA® Gamma Linolenic Acid ("GLA") Safflower Oil Inventory

SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil Inventory

	As of December 31,
	2016		2015
Raw Materials	$	44	$	665
Finished Goods		1,535		1,496
Inventories	$	1,579	$	2,161

Property and Equipment

Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:

	Years
Laboratory equipment	5
Software and computer equipment	3
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

*	Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

Impairment of Long-Lived Assets

Fair Value of Financial Instruments

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

•

Level 3 inputs are unobservable inputs for the asset or liability.

Concentration of Risk

Customer Concentration

Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date.

Customers representing greater than 10% of accounts receivable were as follows (in percentages):

	As of December 31,
	2016		2015
Customer A		—		32
Customer E		36		32
Customer F		1		25
Customer H		27		—
Customer I		22		7

Customers representing greater than 10% of total revenues were as follows (in percentages):

	For Year Ended December 31,
	2016		2015
Customer A		—		12
Customer D		30		22
Customer F		—		14
Customer G		21		13
Customer J		11		5

Stock-Based Compensation

Contract Research Revenues

Government Grant Revenues

Unearned Revenue

The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies.

Research and Development Expenses

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Line Items]

Summary of Inventories

Inventories consist of the following (in thousands):

	As of December 31,
	2016		2015
Raw Materials	$	44	$	665
Finished Goods		1,535		1,496
Inventories	$	1,579	$	2,161

Summary of Average Estimated Useful Lives of Assets

Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets:

	Years
Laboratory equipment	5
Software and computer equipment	3
Furniture and fixtures	7
Vehicles	5
Leasehold improvements	2-10	*

*	Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.

Customer Concentration Risk [Member]

Accounting Policies [Line Items]

Summary of Customer Concentration

Customers representing greater than 10% of accounts receivable were as follows (in percentages):

	As of December 31,
	2016		2015
Customer A		—		32
Customer E		36		32
Customer F		1		25
Customer H		27		—
Customer I		22		7

Customers representing greater than 10% of total revenues were as follows (in percentages):

	For Year Ended December 31,
	2016		2015
Customer A		—		12
Customer D		30		22
Customer F		—		14
Customer G		21		13
Customer J		11		5

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2016

Property Plant And Equipment [Abstract]

Summary of Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	As of December 31,
	2016			2015
Laboratory equipment	$	2,632		$	2,528
Software and computer equipment		449			441
Furniture and fixtures		153			153
Vehicles		204			204
Leasehold improvements		1,991			1,900
Assets under construction		20			18
Property and equipment, gross		5,449			5,244
Less accumulated depreciation and amortization		(4,941	)		(4,659	)
Property and equipment, net	$	508		$	585

Investments and Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2016

Investments And Fair Value Measurements [Abstract]

Summary of Investments in Fixed Income Securities

The Company’s investments in fixed income securities consisted of the following as of December 31, 2016:

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Assets at Fair Value
Cash equivalents:
Money market funds	$	1,549	$	—	$	—		$	1,549
Short-term investments:
Certificates of Deposit		3,049		—		(2	)		3,047
Commercial paper		21,248		—		—			21,248
U.S. government securities		19,267		—		(9	)		19,258
U.S. government agency securities		5,000		—		(6	)		4,994
Long-term investments:
U.S. government securities		2,500		—		(2	)		2,498
Total Assets at Fair Value	$	52,613	$	—	$	(19	)	$	52,594

The Company’s investments in fixed income securities consisted of the following as of December 31, 2015:

(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Assets at Fair Value
Cash equivalents:
Money market funds	$	12,799	$	—	$	—		$	12,799
Commercial paper		5,949		—		—			5,949
U.S. government agency securities		3,049		—		—			3,049
Short-term investments:
Certificates of Deposit		3,374		—		—			3,374
Commercial paper		3,598		—		—			3,598
U.S. government securities		13,678		—		(30	)		13,648
U.S. government agency securities		5,653		1		(4	)		5,650
Long-term investments:
Certificates of Deposit		3,049		—		—			3,049
U.S. government securities		11,780		—		(52	)		11,728
U.S. government agency securities		5,001		—		(30	)		4,971
Total Assets at Fair Value	$	67,930	$	1	$	(116	)	$	67,815

Summary of Fair Value of Available-for-Sale Investments

The fair value of the available-for-sale investments at December 31, 2016 were as follows:

	Fair Value Measurements at December 31, 2016
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	1,549	$	—	$	—	$	1,549
Short-term investments:
Certificates of Deposit		—		3,047		—		3,047
Commercial paper		—		21,248		—		21,248
U.S. government securities		19,258		—		—		19,258
U.S. government agency securities		—		4,994		—		4,994
Long-term investments:
U.S. government securities		2,498		—		—		2,498
Total Assets at Fair Value	$	23,305	$	29,289	$	—	$	52,594

The fair value of the available-for-sale investments at December 31, 2015 were as follows:

	Fair Value Measurements at December 31, 2015
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	12,799	$	—	$	—	$	12,799
Commercial paper		—		5,949		—		5,949
U.S. government agency securities		—		3,049		—		3,049
Short-term investments:
Certificates of Deposit		—		3,374		—		3,374
Commercial paper		—		3,598		—		3,598
U.S. government securities		13,648		—		—		13,648
U.S. government agency securities		—		5,650		—		5,650
Long-term investments:
Certificates of Deposit		—		3,049		—		3,049
U.S. government securities		11,728		—		—		11,728
U.S. government agency securities		—		4,971		—		4,971
Total Assets at Fair Value	$	38,175	$	29,640	$	—	$	67,815

Summary of Changes in Fair Value and Other Adjustments of Derivative Liabilities

The following table sets forth a summary of the changes in the fair value and other adjustments of these derivative liabilities (in thousands):

	Year Ended December 31,
	2016		2015
Beginning balance	$	—	$	1,580
Change in fair value and other adjustments		—		9
Derecognition of derivative liabilities upon debt extinguishment		—		(1,589	)
Ending balance	$	—	$	—

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Investment in Unconsolidated Entity (Tables)

12 Months Ended

Dec. 31, 2016

Limagrain Cereal Seeds LLC [Member]

Summary of Condensed Financial Information Related to Unconsolidated Entity

Summarized condensed financial information related to the unconsolidated entity, accounted for using the equity method is as follows (in thousands):

	As of and for the year ended December 31,
	2016			2015
Assets:
Current assets	$	2,963		$	2,104
Non-current assets		9,776			9,864
Total assets		12,739			11,968
Liabilities and equity:
Current liabilities		26,992			20,807
Equity of Arcadia Biosciences, Inc.(1)		(4,989	)		(3,002	)
Equity of VUSA		(9,264	)		(5,837	)
Total liabilities and equity	$	12,739		$	11,968
Revenue	$	3,635		$	3,630
Gross profit		1,594			1,328
Loss from continuing operations		(5,268	)		(5,509	)
Net loss (2)		(5,413	)		(5,741	)

(1)	Effective June 2014, the investment balance has been reduced to $0.

(2)	As the Company’ investment balance has been reduced to $0 in 2014, the Company’s share of the pretax loss is $0 for the years ended December 31, 2016 and 2015.

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2016

Payables And Accruals [Abstract]

Summary of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands):

	As of December 31,
	2016		2015
Accounts payable—trade	$	222	$	424
Payroll and benefits		1,331		1,050
Research and development		182		323
Royalty fees due to unrelated parties		170		157
Accrued interest on notes payable		98		9
Consulting		29		152
Rent and utilities		85		77
Legal		45		57
Accrued withholding taxes		—		24
Other		197		150
Total accounts payable and accrued expenses	$	2,359	$	2,423

Long-Term Debt and Other Financing Arrangements (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Longterm debt consisted of the following (in thousands):

	December 31, 2016		December 31, 2015
Notes payable	$	25,127	$	24,930
Total	$	25,127	$	24,930
Less current portion		—		—
Long-term portion	$	25,127	$	24,930

Summary of Minimum Principal Payments on Outstanding Debt Related to the Existing Term Loan

Minimum principal payments on the Company’s outstanding debt related to the existing term loan as of December 31, 2016 are as follows (in thousands):

	December 31, 2016
2017	$	—
2018		8,333
2019		8,333
2020		8,334
Total	$	25,000

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Activity Under Stock Incentive Plans

The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share):

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2014		3,759,839		$	3.00	$	12,499
Options granted		352,494			7.30
Options exercised		(609,066	)		0.59
Options cancelled and forfeited		(75,758	)		7.33
Outstanding — Balance at December 31, 2015		3,427,509		$	3.76	$	3,707
Options granted		1,799,395			5.17
Options exercised		(228,141	)		1.18
Options cancelled and forfeited		(419,981	)		4.49
Outstanding — Balance at December 31, 2016		4,578,782			4.38	$	—
Vested and expected to vest — December 31, 2016		4,561,042			4.37	$	—
Exercisable —December 31, 2016		2,804,796		$	3.65	$	—

Weighted-Average Fair Value Assumption of Stock Option Awards

The fair value of stock option awards to employees was estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumption:

	Year Ended December 31,
Assumptions	2016		2015
Expected term (years)	5.40 - 6.25			5.52
Expected volatility	87.80% - 91.40%			100%
Risk-free interest rate	1.17% - 1.54%			1.61%
Expected dividend yield		—		—

Commitment and Contingencies (Tables)

12 Months Ended

Dec. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Minimum Payments Under Non-Cancelable Operating Leases

Future minimum payments under non-cancelable operating leases in effect as of December 31, 2016, are presented below (in thousands):

Years Ending December 31,	Amounts
2017	$	782
2018		334
2019		5
Total future minimum payments under non- cancelable operating leases	$	1,121

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Components of Loss Before Income Taxes

The components of loss before income taxes are as follows:

	Year Ended December 31,
	2016			2015
Domestic	$	(19,599	)	$	(17,930	)
Foreign		—			—
Loss before income taxes	$	(19,599	)	$	(17,930	)

Provision for Income Taxes

The components of the provision for income taxes for the years ended December 31, 2016 and 2015 are as follows (in thousands):

	Year Ended December 31,
	2016		2015
Current:
Federal	$	—	$	—
State		1		2
Foreign		24		24
Total current tax expense		25		26
Deferred:
Federal		—		—
State		—		—
Foreign		—		—
Total deferred tax benefit		—		—
Total tax expense	$	25	$	26

Reconciliation of the Statutory Federal Income Tax Rate

The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:

	Year Ended December 31,
	2016			2015
Expected income tax provision at the federal statutory rate		34.0	%		34.0	%
State taxes, net of federal benefit		4.7	%		4.5	%
Change in valuation allowance		(37.8	)%		(36.8	)%
Nondeductible expenses		(0.9	)%		(1.8	)%
Withholding taxes		(0.1	)%		(0.1	)%
Income tax provision		(0.1	)%		(0.2	)%

Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets are as follows (in thousands)

	As of December 31,
	2016			2015
Deferred tax assets:
Net operating loss carryforwards	$	49,593		$	41,807
Unearned revenue		1,501			1,421
Stock-based compensation		2,861			2,485
Accrued payroll and benefits		215			226
Research and development credits		143			106
Capital loss carryover		13			16
Fixed asset basis difference		191			192
Inventory reserve		1,110			912
Charitable contributions		5			7
Total deferred tax assets		55,632			47,172
Less valuation allowance		(55,632	)		(47,172	)
Net deferred tax assets	$	—		$	—

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Summary of Revenues Based on Location of Customers

Revenues based on the location of the customers, are as follows (in thousands):

	Year Ended December 31,
	2016			2015
United States	$	2,715		$	3,880
India (1)		(100	)		658
Africa		353			293
United Arab Emirates		—			200
Belgium		—			121
France		18			91
Canada		202			75
Other		—			96
Total	$	3,188		$	5,414

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Schedule of Securities Not Included in Diluted per Share Calculations

Securities that were not included in the diluted per share calculations because they would be antidilutive were as follows (in shares):

	Year Ended December 31,
	2016		2015
Options to purchase common stock		4,578,782		3,427,509
Warrants to purchase common stock		1,336,894		1,336,894
Total		5,915,676		4,764,403

Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	May 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Description Of Business [Line Items]
Place of incorporation		Arizona
Year of incorporation		2002
Place of reincorporation		Delaware
Date of reincorporation		2015-03
Reverse split of issued and outstanding common stock		one-for-four
Proceeds from issuance of common stock upon IPO			$ 68,227
Convertible preferred stock, conversion basis		At the closing of the IPO, all of the outstanding shares of convertible preferred stock and redeemable convertible preferred stock were automatically converted into 32,972,793 shares of common stock.
Converted common stock	32,972,793
Preferred stock, outstanding	0
Common stock, authorized	400,000,000	400,000,000	400,000,000
Preferred stock, authorized	20,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, par value	$ 0.001
IPO [Member]
Description Of Business [Line Items]
Common stock, issued and sold	8,528,306
Common stock issued price per share	$ 8.00
Proceeds from issuance of common stock upon IPO	$ 58,400
Underwriting discounts and commissions	4,800
Offering expenses	$ 5,000

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2014
Accounting Policies [Line Items]
Reserved for doubtful accounts	$ 0	$ 0
Write-down of inventory	500,000	600,000
Impairment of long-lived assets	$ 0	0
Maximum [Member]
Accounting Policies [Line Items]
Cost method investment ownership percentage	20.00%
Limagrain Cereal Seeds LLC [Member]
Accounting Policies [Line Items]
Equity method investments	$ 0	0	$ 0
Impairment of equity method investments	$ 0	$ 0

Summary of Significant Accounting Policies - Summary of Average Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2016
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	7 years
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Leasehold improvements [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Leasehold improvements [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	10 years

Summary of Significant Accounting Policies - Summary of Customer Concentration (Detail) - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Accounts Receivable [Member] \| Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage		32.00%
Accounts Receivable [Member] \| Customer E [Member]
Concentration Risk [Line Items]
Concentration risk percentage	36.00%	32.00%
Accounts Receivable [Member] \| Customer F [Member]
Concentration Risk [Line Items]
Concentration risk percentage	1.00%	25.00%
Accounts Receivable [Member] \| Customer H [Member]
Concentration Risk [Line Items]
Concentration risk percentage	27.00%
Accounts Receivable [Member] \| Customer I [Member]
Concentration Risk [Line Items]
Concentration risk percentage	22.00%	7.00%
Total Revenue [Member] \| Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage		12.00%
Total Revenue [Member] \| Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	30.00%	22.00%
Total Revenue [Member] \| Customer F [Member]
Concentration Risk [Line Items]
Concentration risk percentage		14.00%
Total Revenue [Member] \| Customer G [Member]
Concentration Risk [Line Items]
Concentration risk percentage	21.00%	13.00%
Total Revenue [Member] \| Customer J [Member]
Concentration Risk [Line Items]
Concentration risk percentage	11.00%	5.00%

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 5,449	$ 5,244
Less accumulated depreciation and amortization	(4,941)	(4,659)
Property and equipment, net	508	585
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,632	2,528
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	449	441
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	153	153
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	204	204
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,991	1,900
Assets under construction [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 20	$ 18

Investments and Fair Value Measurements - Summary of Investments in Fixed Income Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 52,613	$ 67,930
Unrealized Gains		1
Unrealized Losses	(19)	(116)
Estimated Fair Value	52,594	67,815
Cash Equivalents [Member] \| Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	1,549	12,799
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value	1,549	12,799
Cash Equivalents [Member] \| Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		5,949
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value		5,949
Cash Equivalents [Member] \| U.S. Government Agency Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		3,049
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value		3,049
Short-term Investments [Member] \| Certificates of Deposit [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	3,049	3,374
Unrealized Gains		0
Unrealized Losses	(2)	0
Estimated Fair Value	3,047	3,374
Short-term Investments [Member] \| Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	21,248	3,598
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value	21,248	3,598
Short-term Investments [Member] \| U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	19,267	13,678
Unrealized Gains		0
Unrealized Losses	(9)	(30)
Estimated Fair Value	19,258	13,648
Short-term Investments [Member] \| U.S. Government Agency Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	5,000	5,653
Unrealized Gains		1
Unrealized Losses	(6)	(4)
Estimated Fair Value	4,994	5,650
Long-term investments [Member] \| Certificates of Deposit [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		3,049
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value		3,049
Long-term investments [Member] \| U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	2,500	11,780
Unrealized Gains		0
Unrealized Losses	(2)	(52)
Estimated Fair Value	$ 2,498	11,728
Long-term investments [Member] \| U.S. Government Agency Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		5,001
Unrealized Gains		0
Unrealized Losses		(30)
Estimated Fair Value		$ 4,971

Investments and Fair Value Measurements - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016 USD ($)
Investments Debt And Equity Securities [Abstract]
Investment in continuous unrealized loss position for more than twelve months	$ 0
Maturity of long-term investments	2018

Investments and Fair Value Measurements - Summary of Fair Value of Available-for-Sale Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Assets at Fair Value
Total Assets at Fair Value	$ 52,594	$ 67,815
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	1,549	12,799
Certificates of Deposit [Member]
Assets at Fair Value
Short-term investments	3,047	3,374
Long-term investments		3,049
U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	19,258	13,648
Long-term investments	2,498	11,728
Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		5,949
Short-term investments	21,248	3,598
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	23,305	38,175
Level 1 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	1,549	12,799
Level 1 [Member] \| Certificates of Deposit [Member]
Assets at Fair Value
Short-term investments	0	0
Long-term investments		0
Level 1 [Member] \| U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	19,258	13,648
Long-term investments	2,498	11,728
Level 1 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments	0	0
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	29,289	29,640
Level 2 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 2 [Member] \| Certificates of Deposit [Member]
Assets at Fair Value
Short-term investments	3,047	3,374
Long-term investments		3,049
Level 2 [Member] \| U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	0	0
Long-term investments	0	0
Level 2 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		5,949
Short-term investments	21,248	3,598
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 3 [Member] \| Certificates of Deposit [Member]
Assets at Fair Value
Short-term investments	0	0
Long-term investments		0
Level 3 [Member] \| U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	0	0
Long-term investments	0	0
Level 3 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments	0	0
U.S. Government Agency Securities [Member]
Assets at Fair Value
Cash equivalents		3,049
Short-term investments	4,994	5,650
Long-term investments		4,971
U.S. Government Agency Securities [Member] \| Level 1 [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments	0	0
Long-term investments		0
U.S. Government Agency Securities [Member] \| Level 2 [Member]
Assets at Fair Value
Cash equivalents		3,049
Short-term investments	4,994	5,650
Long-term investments		4,971
U.S. Government Agency Securities [Member] \| Level 3 [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments	$ 0	0
Long-term investments		$ 0

Investments and Fair Value Measurements - Summary of Changes in Fair Value and Other Adjustments of Derivative Liabilities (Detail) - Derivative Financial Instruments Liabilities [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 0	$ 1,580
Change in fair value and other adjustments	0	9
Derecognition of derivative liabilities upon debt extinguishment	0	(1,589)
Ending balance	$ 0	$ 0

Investment in Unconsolidated Entity - Additional information (Detail) - Limagrain Cereal Seeds LLC [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Investment, ownership percentage	35.00%
Loss on investments	$ 0	$ 0
Vilmorin Cie [Member]
Schedule of Equity Method Investments [Line Items]
Investment, remaining ownership percentage	65.00%
Vilmorin USA [Member]
Schedule of Equity Method Investments [Line Items]
Debt balance	$ 25,000,000
Maturity date of debt	Apr. 15, 2017

- Definition

This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.

+ References + Details

Investment in Unconsolidated Entity - Summary of Condensed Financial Information Related to Unconsolidated Entity (Detail) - Limagrain Cereal Seeds LLC [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Assets:
Current assets	$ 2,963	$ 2,104
Non-current assets	9,776	9,864
Total assets	12,739	11,968
Liabilities and equity:
Current liabilities	26,992	20,807
Total liabilities and equity	12,739	11,968
Revenue	3,635	3,630
Gross profit	1,594	1,328
Loss from continuing operations	(5,268)	(5,509)
Net loss	(5,413)	(5,741)
Arcadia Biosciences, Inc [Member]
Liabilities and equity:
Equity	(4,989)	(3,002)
Vilmorin USA [Member]
Liabilities and equity:
Equity	$ (9,264)	$ (5,837)

Investment in Unconsolidated Entity - Summary of Condensed Financial Information Related to Unconsolidated Entity (Parenthetical ) (Detail) - Limagrain Cereal Seeds LLC [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2014
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 0	$ 0	$ 0
Share of pretax loss	$ 0	$ 0

Variable Interest Entity - Additional Information (Detail)	1 Months Ended		12 Months Ended			20 Months Ended
	Sep. 30, 2014 USD ($) shares	Feb. 29, 2012 Soybean_Grower	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($)	Aug. 31, 2014 USD ($)
Variable Interest Entity [Line Items]
Variable interest entity agreement, terms			Both the Company and Bioceres incur expenses in support of specific activities agreed, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period.
Funding period of cash required for contributed services			4 years
Aggregate value of common stock purchased						$ 2,000,000
Number of shares surrendered \| shares	1,832
Research agreement settled				$ 205,000
Number of share remaining \| shares				632
Fair value of share held				$ 500,000
Cost method investment				0
Direct and allocated overhead amount			$ 416,000	$ 1,300,000
Research And Development Expense [Member]
Variable Interest Entity [Line Items]
VIE agreement amendment expense					$ 1,500,000
Amended Purchase Commitment Of Common Stock [Member]
Variable Interest Entity [Line Items]
Commitment to purchase stock in 2014	$ 500,000
Maximum [Member]
Variable Interest Entity [Line Items]
Commitment to purchase stock			5,000,000
Maximum [Member] \| Purchase Commitment of Common Stock [Member]
Variable Interest Entity [Line Items]
Commitment to purchase stock in 2014			2,000,000
Commitment to purchase stock in 2015			$ 1,200,000
Bioceres, S.A. [Member]
Variable Interest Entity [Line Items]
Number of soybean growers owned \| Soybean_Grower		250

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Accounts payable—trade	$ 222	$ 424
Payroll and benefits	1,331	1,050
Research and development	182	323
Royalty fees due to unrelated parties	170	157
Accrued interest on notes payable	98	9
Consulting	29	152
Rent and utilities	85	77
Legal	45	57
Accrued withholding taxes	0	24
Other	197	150
Total accounts payable and accrued expenses	$ 2,359	$ 2,423

Accounts Payable and Accrued Expenses - Exit or Disposal Activities - Additional Information (Details)	12 Months Ended
	Dec. 31, 2016 USD ($) Position
Payables And Accruals [Line Items]
Number of positions eliminated \| Position	23
Other restructuring costs	$ 0
One-Time Employee Termination Benefits [Member]
Payables And Accruals [Line Items]
Severance cost accrued under payroll and benefits	389,000
One-Time Employee Termination Benefits [Member] \| Selling, General, and Administrative Expense [Member]
Payables And Accruals [Line Items]
Severance costs	192,000
Executive Employment Contract [Member] \| Selling, General, and Administrative Expense [Member]
Payables And Accruals [Line Items]
Severance costs	$ 224,000

Long-Term Debt and Other Financing Arrangements - Summary of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Notes payable	$ 25,127	$ 24,930
Total	25,127	24,930
Less current portion	0	0
Long-term portion	$ 25,127	$ 24,930

Long-Term Debt and Other Financing Arrangements - Term Note Related Party - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2015	Jul. 31, 2012	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Repayment of principal balance				$ 8,000,000
Repayment of accrued interest and prepayment fee			$ 1,319,000	2,658,000
Loss on extinguishment of debt			$ 0	(230,000)
Moral Compass Corporation [Member]
Debt Instrument [Line Items]
Note payable		$ 8,000,000
Moral Compass Corporation [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Note payable		$ 8,000,000
Debt instrument term		36 months
Moral Compass Corporation [Member] \| Amended Term Note [Member]
Debt Instrument [Line Items]
Repayment of principal balance	$ 8,000,000
Repayment of accrued interest and prepayment fee	$ 148,000
Loss on extinguishment of debt				$ (80,000)

Long-Term Debt and Other Financing Arrangements - Promissory Notes - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Nov. 30, 2013	Aug. 31, 2013
Debt Instrument [Line Items]
Repayment of accrued interest and prepayment fee		$ 1,319,000	$ 2,658,000
Loss on extinguishment of debt		$ 0	(230,000)
Promissory Notes [Member]
Debt Instrument [Line Items]
Notes Payable to Unrelated Party				$ 1,100,000	$ 2,000,000
Repayment of principal balance	$ 1,600,000
Repayment of accrued interest and prepayment fee	$ 44,000
Loss on extinguishment of debt			$ (37,000)

Long-Term Debt and Other Financing Arrangements - Convertible Promissory Notes - Additional Information (Detail)	1 Months Ended		12 Months Ended
	May 31, 2015 USD ($)	Apr. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2015 USD ($) Installment	Dec. 31, 2013 USD ($) $ / shares shares	Sep. 30, 2013 USD ($)
Debt Instrument [Line Items]
Interest expense related to debt discount			$ 198,000	$ 837,000
Increase in fair value of warrant			197,000
Fees paid to lender			46,000	396,000
Loss on extinguishment of debt			0	(230,000)
Accrued interest			98,000	9,000
Repayment of accrued interest and prepayment fee			$ 1,319,000	2,658,000
Mahyco Convertible Promissory Note One [Member]
Debt Instrument [Line Items]
Debt instrument, face amount						$ 500,000
Mahyco Convertible Promissory Note Two [Member]
Debt Instrument [Line Items]
Debt instrument, face amount					$ 4,500,000
Mahyco Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Debt instrument term			5 years
Conversion price \| $ / shares			$ 16.52
Percentage of price per share of recent offering for conversion price per share of notes outstanding			90.00%
Number of warrant to purchase common stock issued \| shares					75,666
Common stock warrants, exercise price per share \| $ / shares					$ 16.52
Warrant, vesting date			2013-12
Warrant, exercisable term			5 years
Interest expense related to convertible promissory note				747,000
Interest expense related to debt discount				536,000
Mahyco Convertible Promissory Notes [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Interest on the notes			2.00%
Additional Mahyco Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 5,000,000
Debt instrument term			5 years
Convertible debt			$ 5,000,000
Term Loan Borrowings from Unrelated Parties [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 20,000,000
Common stock warrants, exercise price per share \| $ / shares		$ 5.32
Interest expense related to convertible promissory note				1,500,000
Interest expense related to debt discount				301,000
Interest rate terms description			Under this loan agreement, interest on the Term Loans accrued at a rate per annum equal to the greater of (i) 9.0% and (ii) a fluctuating rate of interest equal to threemonth LIBOR as in effect from time to time plus 8.74%.
Repayment date of outstanding principal amounts and accrued interest			Nov. 01, 2018
Additional term payment due on maturity of term loan		$ 600,000
Common stock warrants issued \| shares		1,503,760
Warrant liability, fair value		$ 356,000
Embedded derivative liability, fair value		$ 81,000
Fees paid to lender				290,000
Initial fair value of warrants and embedded derivative liability	$ 437,000
Debt instrument, violation or event of default description			In July 2015, the Company amended the Term Loans to include collateral of certain intellectual property rights in exchange for a waiver of the Company’s obligation to obtain a subordination agreement from Mahyco International with respect to the indebtedness the Company owed to them. In an event of default, the lenders could have accelerated and declared to be immediately due and payable the outstanding principal amount of the Term Loans and the Company’s other payment obligations under the agreement. In the case of a bankruptcy or insolvency event of default, the outstanding principal amount of the Term Loans and the Company’s other payment obligations under the loan agreement automatically would have accelerated and become due and payable. In addition, if an event of default occurred and continued under the loan agreement, the lenders could have exercised certain additional secured creditor remedies against the Company and against the assets that secured the Company’s obligations under the agreement.
Term Loan Borrowings from Unrelated Parties [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Stated interest rate on loan		9.00%
Term Loan Borrowings from Unrelated Parties [Member] \| Three-month LIBOR [Member]
Debt Instrument [Line Items]
Interest on the notes		8.74%
Senior Secured Term Loan Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 25,000,000	$ 25,000,000
Repayment date of outstanding principal amounts and accrued interest				Dec. 01, 2020
Additional term payment due on maturity of term loan				$ 600,000
Repayment of principal balance				20,000,000
Accrued interest, prepayment and other fees				1,300,000
Loss on extinguishment of debt				(1,200,000)
Unamortized debt discount				427,000
Deferred loan issuance fees				$ 58,000
Number of installments \| Installment				36
Cash collateralized obligations			100.00%
Senior Secured Term Loan Facility [Member] \| Prepayment Occurs After December 29, 2016 but Before December 29, 2017 [Member]
Debt Instrument [Line Items]
Prepayment fee as of outstanding principal amount percentage				3.00%
Senior Secured Term Loan Facility [Member] \| Prepayment Occurs After December 29, 2017 [Member]
Debt Instrument [Line Items]
Prepayment fee as of outstanding principal amount percentage				1.00%
Senior Secured Term Loan Facility [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Liquidity ratio			140.00%
Senior Secured Term Loan Facility [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Interest on the notes				0.90%
New Term Loan Facility [Member]
Debt Instrument [Line Items]
Convertible debt				$ 5,000,000
Repayment of principal balance				3,700,000
Accrued interest				154,000
Derivative liabilities				$ 1,600,000

Long-Term Debt and Other Financing Arrangements - Summary of Minimum Principal Payments on Outstanding Debt Related to the Existing Term Loan (Detail) - Senior Secured Term Loan Facility [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
2018	$ 8,333
2019	8,333
2020	8,334
Total	$ 25,000	$ 25,000

Stock-Based Compensation - Additional Information (Detail)			12 Months Ended
	May 20, 2015 shares	May 14, 2015 shares	Dec. 31, 2016 USD ($) IncentivePlan $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans \| IncentivePlan			2
Total number of options outstanding			4,578,782	3,427,509	3,759,839
Intrinsic value of options exercised \| $			$ 0	$ 1,500,000
Options expired in period			0	0
Total fair value of shares vested \| $			$ 283,000	$ 730,000
Unrecognized compensation cost related to unvested stock-based compensation grants \| $			$ 1,700,000
Weighted-average remaining recognition period			3 years 1 month 13 days
Weighted-average estimated grant-date fair value of stock options granted \| $ / shares			$ 1.13	$ 4.64
Stock-based compensation \| $			$ 1,059,000	$ 1,392,000
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan		625,000
Stock-based compensation \| $			$ 80,000	$ 69,000
Percentage in payroll deductions to acquire shares of common stock		15.00%
Purchase plan offering period		6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage		85.00%
Issuance of common stock pursuant to employee stock purchase plan			75,342
First offering period, start date		May 14, 2015
First offering period, end date		Feb. 01, 2016
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan	212,729
Total number of options outstanding			2,878,536
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period	4 years
Terms under the plan			The 2015 Plan became effective upon the IPO and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,087,729 shares of common stock reserved for future issuance, which included 212,729 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016. In addition, shares subject to awards under the 2006 Plan that are forfeited or terminated will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan	3,087,729		5,223,245
Common stock available for future grant			3,522,999
Total number of options outstanding			1,700,246
2015 Omnibus Equity Incentive Plan [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vesting percentage at end of one year	25.00%
Minimum [Member] \| Unvested Options [Member] \| 2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			2 years 3 months
Maximum [Member] \| 2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period	10 years
Maximum [Member] \| Unvested Options [Member] \| 2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period			4 years

Stock-Based Compensation - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	3,427,509	3,759,839
Shares Subject to Outstanding, Options granted	1,799,395	352,494
Shares Subject to Outstanding, Options exercised	(228,141)	(609,066)
Shares Subject to Outstanding, Options cancelled and forfeited	(419,981)	(75,758)
Shares Subject to Outstanding, Ending Balance	4,578,782	3,427,509
Shares Subject to Outstanding, Vested and expected to vest	4,561,042
Shares Subject to Outstanding, Exercisable	2,804,796
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 3.76	$ 3.00
Weighted-Average Exercise Price Per Share, Options granted	5.17	7.30
Weighted-Average Exercise Price Per Share, Options exercised	1.18	0.59
Weighted-Average Exercise Price Per Share, Options cancelled and forfeited	4.49	7.33
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	4.38	$ 3.76
Weighted Average Exercise Price Per Share, Vested and expected to vest	4.37
Weighted Average Exercise Price Per Share, Exercisable	$ 3.65
Aggregate Intrinsic Value, Outstanding Balance		$ 3,707	$ 12,499

Stock-Based Compensation - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)		5 years 6 months 7 days
Expected volatility		100.00%
Risk-free interest rate		1.61%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 3 months
Expected volatility	91.40%
Risk-free interest rate	1.54%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years 4 months 24 days
Expected volatility	87.80%
Risk-free interest rate	1.17%

Commitments and Contingencies - Additional Information (Detail)		12 Months Ended
	Dec. 31, 2010 USD ($) Program	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Jun. 15, 2005 USD ($)
Commitments And Contingencies [Line Items]
Operating leases rent expense		$ 1,300,000	$ 1,300,000
Other noncurrent liability		3,000,000	3,000,000
Royalties due to both related and unrelated parties on license revenue accrued		201,000	177,000
Milestones payments yet to be achieved		2,000,000	2,000,000
Milestones payment		$ 0	$ 0
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability	$ 3,000,000			$ 5,000,000
Date of merger and reorganization		Jun. 15, 2005
Restructuring activities, description		As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased \| Program	3
Number of development programs \| Program	6
Other noncurrent liability		$ 3,000,000
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		3 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		2.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements		15.00%

Commitments and Contingencies - Future Minimum Payments Under Non-Cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2017	$ 782
2018	334
2019	5
Total future minimum payments under non- cancelable operating leases	$ 1,121

Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Domestic	$ (19,599)	$ (17,930)
Foreign	0	0
Net loss before income taxes	$ (19,599)	$ (17,930)

Income Taxes - Components of the Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal	$ 0	$ 0
State	1	2
Foreign	24	24
Total current tax expense	25	26
Deferred:
Federal	0	0
State	0	0
Foreign	0	0
Total deferred tax benefit	0	0
Total tax expense	$ 25	$ 26

Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Expected income tax provision at the federal statutory rate	34.00%	34.00%
State taxes, net of federal benefit	4.70%	4.50%
Change in valuation allowance	(37.80%)	(36.80%)
Nondeductible expenses	(0.90%)	(1.80%)
Withholding taxes	(0.10%)	(0.10%)
Income tax provision	(0.10%)	(0.20%)

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Income Tax [Line Items]
Total income tax expense	$ 25,000	$ 26,000
Net valuation allowance increased	$ 8,500,000	$ 6,600,000
Operating loss carryforwards limitations on use	it has not forfeited the right to carryforward tax losses up to 20 years
Tax years open back to extent of NOLs being carried forward	2000
Uncertain Tax Position	$ 0
Maximum [Member]
Schedule Of Income Tax [Line Items]
Right to carryforward tax losses, period	20 years
Tax year subject to examination by the tax authorities	2016
Minimum [Member]
Schedule Of Income Tax [Line Items]
Tax year subject to examination by the tax authorities	2006
Federal [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 136,200,000
Operating loss carryforward unutilized	7,200,000
State [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 100,300,000

Income Taxes - Summary of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 49,593	$ 41,807
Unearned revenue	1,501	1,421
Stock-based compensation	2,861	2,485
Accrued payroll and benefits	215	226
Research and development credits	143	106
Capital loss carryover	13	16
Fixed asset basis difference	191	192
Inventory reserve	1,110	912
Charitable contributions	5	7
Total deferred tax assets	55,632	47,172
Less valuation allowance	(55,632)	(47,172)
Net deferred tax assets	$ 0	$ 0

Retirement Benefits - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Employer matching contribution, percent	50.00%
Maximum annual contribution per employee, percent	3.00%
Description of defined contribution pension and other postretirement plans	Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment.
Defined benefit plan employee vested minimum period, years	1 year
Amount accrued for company's approved discretionary match	$ 0	$ 0

Segment and Geographic Information - Summary of Revenues Based on Location of Customers (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

$ 3,188

$ 5,414

United States

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

2,715

3,880

India

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

^[1]

(100)

658

Africa

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

353

293

United Arab Emirates

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

200

Belgium

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

121

France

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

Canada

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

$ 202

Other

Revenues From External Customers And Long Lived Assets [Line Items]

Total revenues

$ 96

[1]	The negative amount is due to the change in estimated commercialization dates in 2016, which impacted the timing of revenue recognition.

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	5,915,676	4,764,403
Option to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	4,578,782	3,427,509
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	1,336,894	1,336,894

Related Party Transactions - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jul. 31, 2012
Related Party Transaction [Line Items]
Royalty fees due	$ 30,000	$ 19,000
Revenue recognized	0	91,000
Moral Compass Corporation [Member]
Related Party Transaction [Line Items]
Note payable			$ 8,000,000
Blue Horse Labs Inc [Member]
Related Party Transaction [Line Items]
Royalty fees due	$ 30,000	19,000
Limagrain Cereal Seeds LLC [Member]
Related Party Transaction [Line Items]
Revenue recognized		$ 91,000

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Event On February 14, 2017, the Company received a letter from Nasdaq notifying us that we were not in compliance with the minimum close bid requirement set forth in Nasdaq Listing Rule 5405. In accordance with Nasdaq Listing Rule 5450(a)(1), we are provided with a cure to regain compliance until August 14, 2017.

Consolidated Statements of Redeemable and Convertible Preferred Stock and Stockholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Common Stock [Member]
Issuance of common stock upon the IPO, issuance costs	$ 9,799

Summary of Significant Accounting Policies - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw Materials	$ 44	$ 665
Finished Goods	1,535	1,496
Inventories	$ 1,579	$ 2,161